The tumor cells of AITL, DLBCL, and MDS in this patient shared common mutations in TET2 and DNMT3A, suggesting that hematologic malignancies in the three lineages evolved from a common founder clone. This evidence concerns the gene TET2 and myelodysplastic syndrome.